Central Nervous System as Possible Site of Relapse in ERBB2-Positive Metastatic Colorectal Cancer: Long-term Results of Treatment With Trastuzumab and Lapatinib.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 32324210.
- Also identified by DOI 10.1001/jamaoncol.2020.0571 and PMC identifier 7180725.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This secondary analysis of data from the HERACLES-A clinical trial examines long-term outcomes in 32 patients with colorectal cancer treated with trastuzumab and lapatinib.
Medical subject headings
- Antineoplastic Agents
- Central Nervous System Neoplasms
- Colorectal Neoplasms
- Lapatinib
- Protein Kinase Inhibitors
- Erb-b2 Receptor Tyrosine Kinases
- Trastuzumab